Day 2 – Thursday, 17 September 2025Wednesday, September 17, 2025 - ET (Eastern Time, GMT-05:00)

Major players in the tech space, with market caps orders of magnitude greater than traditional healthcare companies, are starting to make their move into the healthcare market. Could this transition provide a catalyst for growth within the healthcare sector? Our panel of big tech executives, and CEOs who have partnered with them, share their experiences from communicating and partnering with big tech.

• Strategies for engaging with big tech in the healthcare landscape
• How partnerships with big tech differ from traditional life science strategics
• Value provided by big tech to medtech companies

For medtech companies, reimbursement can prove the final hurdle before long-term commercial success. Yet, for many, the process is not considered early enough, leading to costly delays and additional investigations to prove value. Hear insights from CEOs, strategics and investors on successful reimbursement strategy among what may be a rapidly reformed CMS landscape.

• Potential for CMS reform and what it may mean
• Case studies in successful reimbursement strategy and the learnings newer companies can take
• Importance of considering reimbursement prior to regulatory approval

In today's digital age, the lines between commercial operations, R&D, and customer engagement are blurring. This panel explores how shared digital technologies can break down internal silos within pharma while simultaneously enhancing customer experiences. We'll discuss the strategic implementation of unified platforms, data-driven approaches, and seamless digital interactions to create a cohesive and patient-centric ecosystem.

• How can we break down the silos between Commercial & R&D for pharma success?
• Discussing how integrated data platforms and AI-powered analytics can facilitate faster decision-making and streamline the drug development process
• Exploring how shared digital tools can provide real-time market insights, patient feedback, and payer data to optimize product positioning and launch strategies
• Examining the importance of fostering a culture of cross-functional collaboration and digital literacy to ensure the successful implementation and adoption of shared technologies

Explore how pharmaceutical companies are leveraging generative AI to revolutionize omnichannel engagement. This panel will discuss how AI-driven analytics and technology are illuminating hidden insights in data, enabling hyper-personalization, and driving better health outcomes. Discover how pharma is orchestrating personalized communications and interactions that resonate with stakeholders at every stage of their journey.

• Understanding the evolution and the importance of a coordinated omnichannel approach in pharma marketing and communications
• Discussing how generative AI can rapidly produce tailored content, enhance field force training, and provide 24/7 support to HCPs and patients
• Exploring strategies to address challenges in AI implementation, fostering cross-functional collaboration, and ensuring data quality and ethical use

Emerging therapeutic trends have taken centre stage this year – from breakthroughs in precision oncology and neuroscience to cutting-edge autoimmune therapies and epigenetics, the future is being driven by bold innovation and strategic collaboration.

These transformative trends are reshaping the therapeutic landscape, reflecting the industry's focus on meeting unmet medical needs, integrating advanced technologies, and pushing the boundaries of patient-centric care. This panel will dive into the most promising therapeutic advancements that are redefining biopharma and healthcare in 2025.

• Renewed Innovation: The rise of new game-changers in across therapeutic areas
• How are deal makers mitigating risk when it comes to approaching new opportunities?
• Expectations for the remainder of the year as we begin to look to 2026

In the fast-paced world of drug development, early-stage partnerships are often the catalyst for groundbreaking innovations. These collaborations enable smaller biotech firms to access critical resources and expertise, while larger pharma companies gain access to cutting-edge ideas and technologies. However, navigating the complexities of early-stage partnerships requires careful alignment of goals, clear communication, and a shared vision for success. This panel will explore the unique dynamics of early-stage pharma partnering, uncovering the keys to fostering successful collaborations that pave the way for life-changing therapies.

• Strategies for identifying partners with complementary expertise, aligned goals, and a shared commitment to innovation
• Best practices for negotiating agreements, defining roles, and managing intellectual property in early-stage collaborations
• Addressing common hurdles and risk-sharing in partnerships

Manufacturing agreements are critical for biopharma companies seeking to scale production without the high capital costs of building in-house facilities. These partnerships with CMOs or larger pharma companies help bring products to market faster but also introduce dependencies and quality control challenges.

• Choosing the right manufacturing partner: Key considerations for biotech companies
• Managing dependencies while maintaining quality control in outsourced production
• Balancing cost efficiency with flexibility in manufacturing agreements

As we race through 2025, the biotech landscape is evolving faster than ever, driven by new technologies, shifting market dynamics, and growing patient expectations. Early commercialisation planning is no longer a "nice-to-have" but a critical differentiator in achieving success. This panel explores how biotech companies can adapt to this new era by aligning R&D with real-world demands, leveraging advanced data tools, and fostering partnerships earlier in the development cycle. Join industry experts as they share forward-looking strategies to navigate these changes and set the foundation for impactful, market-ready innovation.

• Forging strategic partnerships earlier to accelerate commercial readiness in an increasingly competitive space
• Embracing cross-functional collaboration to streamline the transition from clinical trials to market
• Adapting to new patient and provider expectations in a post-pandemic, tech-driven healthcare ecosystem

Diving into real-world experiences of biotech leaders who have navigated the complexities of launching their first product, rom unexpected hurdles to innovative breakthroughs, this discussion will highlight what it truly takes to succeed in the high-stakes environment of first-time launches. Attendees will gain practical insights into overcoming challenges, leveraging opportunities, and avoiding common pitfalls.

• The importance of starting functional preparations early and investing in key areas
• Overcoming common pitfalls such as underestimating market access challenges
• Lessons learned from both successful and less successful first-time launches

In order to deliver on the promise of delivering innovative medicine to patients, biotech companies need to consider how they can scale up. As a biotech grows and continues to attract significant capital, what do leaderships teams need to consider outside of its core assets?

• Building a commercial organisation vs remaining pure R&D
• How many pipeline assets does it take to ‘win’? What a pipeline to support a mature biotech business looks like
• Is there an ideal number of therapeutic areas to enter?
• Collaborate vs go it alone

Founding a company is a daunting task, especially for first-time founders experiencing the highs and lows of entrepreneurship for the first time. We bring together investors and experienced medtech executives to discuss areas of commercialization which are often undervalued and neglected, and the value created by getting these aspects right.

• Areas which can often be overlooked by medtech founders
• The importance of having experience within the leadership team at a C-suite and board level
• Building for long-term success from day one

The USA has long been the first choice for life science commercialization, but where should companies go from there? With EUMDR creating uncertainty in Europe and increased interest in Asia and the Middle East, there is arguably more choice than ever before for global expansion. Our panel will delve in to the realities of global markets, strategies for getting there and how to know which market is best for your company.

• How to know when your company is ready for global expansion
• Finding partners and support in new markets
• Cultural and macroeconomic differences in different geographies and how they impact medtech

Medtech investment increased drastically between 2020 and 2021 in the height of the COVID-19 pandemic, riding the wave of increased investor interest and a wave of IPOs medtech valuations surged to unprecedented levels. These valuations naturally subsided through the lack of exits observed in the years since COVID, but with exits returning in the form of both IPOs and M&A investors are seeing real world examples of return on investments. Our panel of investors and medtech leaders discuss the future of valuations and expectations for investors and startups.

• The valuation correction and its impact
• What goes into a medtech company valuation
• Valuation expectations moving forward

Explore the transformative power of AI in Medical Affairs. This panel delves into how AI-driven insights are enhancing strategic decision-making, streamlining operations, and ultimately improving patient outcomes. Discover how Medical Affairs teams are leveraging AI to navigate the complexities of the digital landscape and deliver impactful results.

• How AI is enabling Medical Affairs teams to efficiently analyse vast amounts of data, identify key trends, and generate actionable insights
• Discussing how AI-powered tools are improving communication and collaboration with healthcare professionals, patients, and other stakeholders
• Exploring how AI-driven insights are informing key decisions in Medical Affairs, leading to more effective strategies and improved outcomes

Technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless.

• What are the biggest challenges to centralizing, standardizing, and managing data? How are pharma overcoming those challenges?
• What is the next frontier when it comes to data-driven solutions? What are the tools being developed right now that will transform the way we approach healthcare?
• What role does AI play in this? Where do you see the most potential for healthcare to benefit from the current AI tide?

The 2024 re-election of the Trump administration marked a pivotal moment for the life sciences industry, ushering in a wave of potential policy shifts. This panel will examine how the industry has navigated the first year of this administration, potential changes to drug pricing, and the evolving role of regulatory bodies.

The discussion will also delve into how companies are preparing for long-term impacts, addressing pressing questions around access, affordability, and the future of innovation. Attendees will gain insight into the strategies industry leaders are deploying to adapt to the shifting landscape, maintain patient safety, and continue delivering transformative therapies.

• Examining the repeal of key healthcare legislation and its effects on drug pricing, access, and market dynamics
• Analysing the evolving role of the FDA health policy
• Comparing US healthcare outcomes with global systems and addressing challenges in affordability and innovation
• Strategies and future outlook – Exploring how companies are navigating uncertainty, maintaining compliance, and driving innovation amidst political change

The field of neuroscience is experiencing a transformative era, with groundbreaking advancements reshaping how we understand and treat complex brain conditions. From revolutionary therapies in biopharma to cutting-edge medical devices and the integration of digital health solutions, innovation is unlocking new possibilities for addressing neurological disorders. This panel will bring together thought leaders from across life sciences to discuss how their respective industries are contributing to this progress, the challenges they face, and the opportunities for collaboration. As neuroscience remains a critical frontier in medicine, the panel will explore how these innovations are improving patient outcomes and paving the way for a future where brain health is prioritised like never before.

• The impact of AI, machine learning, and advanced imaging on accelerating neuroscience research and treatment development
• Leveraging genomics and biomarkers to create tailored approaches for neurological disorders
• Patient-centric innovation and prioritising patient needs through real-world data, digital tools, and collaborative care models
• Collaboration: Bridging biopharma, medtech, and digital health to drive unified solutions for brain health challenges